Pubblicazioni (scarica PDF) - Istituto Nazionale dei Tumori

Annexes
1. Di Cosimo S, Bregni G, Daidone MG, Cinquini M, de Braud F, Torri V. Waiting for
Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer.
Breast. 2016 Apr 22. pii: S0960-9776(16)00017-5. doi: 10.1016/j.breast.2016.02.002.
2. Falanga A, Santoro A, Labianca R, De Braud F, Gasparini G, D'Alessio A, Barni S,
Iacoviello L; HYPERCAN Study Group. Hypercoagulation screening as an innovative
tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN
study. Thromb Res. 2016 Apr;140 Suppl 1:S55-9. doi: 10.1016/S0049-3848(16)300998.
3. Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini
R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Pacifici M, Coppa
J, Mazzaferro V, de Braud F, Porta C, Escudier B, Procopio G. Clinical Impact of
Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
PLoS One. 2016 Apr 11;11(4):e0151662. doi: 10.1371/journal.pone.0151662. eCollection
2016
4. Pusceddu S, De Braud F, Lo Russo G, Concas L, Femia D, Vernieri C, Indini A,
Formisano B, Buzzoni R. How do the results of the RADIANT trials impact on the
management of NET patients? A systematic review of published studies. Oncotarget. 2016
Apr 5. doi: 10.18632/oncotarget.8601. Review
5. Pelosi G, Pellegrinelli A, Fabbri A, Tamborini E, Perrone F, Settanni G, Busico A, Picciani
B, Testi MA, Militti L, Maisonneuve P, Valeri B, Sonzogni A, Proto C, Garassino M, De
Braud F, Pastorino U. Deciphering intra-tumor heterogeneity of lung adenocarcinoma
confirms that dominant, branching, and private gene mutations occur within individual
tumor nodules. Virchows Arch. 2016 Apr 7.
6. Falvella FS, Cremolini C, Miceli R, Nichetti F, Cheli S, Antoniotti C, Infante G, Martinetti
A, Marmorino F, Sottotetti E, Berenato R, Caporale M, Colombo A, de Braud F, Di
Bartolomeo M, Clementi E, Loupakis F, Pietrantonio F. Variant alleles in factor V,
prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and
risk of thromboembolism in metastatic colorectal cancer patients treated with first-line
chemotherapy plus bevacizumab. Pharmacogenomics J. 2016 Mar 22. doi:
10.1038/tpj.2016.22.
7. Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, UroCoste E, de Braud F, Pelosi G, French CA. Clinical Response of Carcinomas Harboring
the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK8628. Cancer Discov. 2016 May;6(5):492-500.
8. Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M,
Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC. Treatment of
lung large cell neuroendocrine carcinoma.Tumour Biol. 2016 Mar 4.
9. Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M,
Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F,
Garassino MC. Diagnosis and management of typical and atypical lung carcinoids.Crit Rev
Oncol Hematol. 2016 Apr;100:167-76. doi: 10.1016/j.critrevonc.2016.02.009. Review.
10. Giampieri R, Caporale M, Pietrantonio F, De Braud F, Negri FV, Giuliani F, Pusceddu V,
Demurtas L, Restivo A, Fontanella C, Aprile G, Cascinu S, Scartozzi M. Second-line
angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or
overcrowded?
Crit
Rev
Oncol
Hematol.
2016
Apr;100:99-106.
doi:
10.1016/j.critrevonc.2016.02.005. Review.
11. Pusceddu S, Buzzoni R, Vernieri C, Concas L, Marceglia S, Giacomelli L, Milione M,
Leuzzi L, Femia D, Formisano B, Mazzaferro V, de Braud F. Metformin with everolimus
and octreotide in pancreatic neuroendocrine tumor patients with diabetes. Future Oncol.
2016 May;12(10):1251-60. doi: 10.2217/fon-2015-0077.
12. Necchi A, Lo Vullo S, Mariani L, Raggi D, Giannatempo P, Calareso G, Togliardi E,
Crippa F, Di Genova N, Perrone F, Colecchia M, Paolini B, Pelosi G, Nicolai N, Procopio
G, Salvioni R, De Braud FG. An open-label, single-arm, phase 2 study of the Aurora
kinase A inhibitor alisertib in patients with advanced urothelial cancer. Invest New Drugs.
2016 Apr;34(2):236-42. doi: 10.1007/s10637-016-0328-9.
13. Pelosi G, Perrone F, Tamborini E, Fabbri A, Testi MA, Busico A, Settanni G, Picciani B,
Bovio E, Sonzogni A, Valeri B, Garassino M, De Braud F, Pastorino U. Doing more with
less: fluorescence in situ hybridization and gene sequencing assays can be reliably
performed on archival stained tumor tissue sections. Virchows Arch. 2016 Apr;468(4):45161. doi: 10.1007/s00428-016-1906-0.
14. Indini A, Di Nicola M, Del Vecchio M, De Braud F. Immune Suppression and Response
to Ipilimumab: Assessing Risk-to-Benefit Ratio. J Clin Oncol. 2016 Jan 19. pii: JCO650028.
[Epub ahead of print] No abstract available. PMID:26786928
15. Fazio N, Biffi R, Maibach R, Hayoz S, Thierstein S, Brauchli P, Bernhard J, Stupp R,
Andreoni B, Renne G, Crosta C, Morant R, Chiappa A, Luca F, Zampino MG, Huber O,
Goldhirsch A, de Braud F, Roth AD; Swiss Group for Clinical Cancer Research (SAKK)
and the European Institute of Oncology (IEO), Milan, Italy. Pre-operative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced
resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. Ann
Oncol. 2015 Dec 27. pii: mdv620.
16. Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini
E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E,
Villa A, Santinami M, De Braud F, Rivoltini L, Rodolfo M. Overcoming melanoma
resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Oncotarget. 2015 Dec 14. doi: 10.18632/oncotarget.6599.
17. Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, de
Braud F, Mortarini R, Anichini A. Primary cross-resistance to BRAFV600E-, MEK1/2and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual
pathway blockade. Oncotarget. 2015 Dec 14. doi: 10.18632/oncotarget.6600.
18. Goff LW, Cohen RB, Berlin J, De Braud FG, Lyshchik A, Noberasco C, Bertolini F,
Carpentieri M, Gallo Stampino C, Abbattista A, Wang E, Borghaei H. A Phase I Study of
the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in
Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Dec 11. pii:
clincanres.1622.2015.
19. Zanardi E, Bregni G, de Braud F, Di Cosimo S. Better Together: Targeted Combination
Therapies in Breast Cancer. Semin Oncol. 2015 Dec;42(6):887-95. doi:
10.1053/j.seminoncol.2015.09.029. Epub 2015 Sep 24. Review
20. Catania C, Feroce I, Barile M, Goldhirsch A, De Pas T, de Braud F, Boselli S, Adamoli L,
Radice D, Rossi A, Spitaleri G, Noberasco C, Bonanni B. Improved health perception after
genetic counselling for women at high risk of breast and/or ovarian cancer: construction of
new questionnaires-an Italian exploratory study. J Cancer Res Clin Oncol. 2015 Nov 17
21. Pietrantonio F, de Braud F, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F,
Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F,
Federici S, Di Bartolomeo M. Dose-Dense Temozolomide in Patients with MGMTSilenced Chemorefractory Colorectal Cancer. Target Oncol. 2015 Nov 4
22. Iacovelli R, Pietrantonio F, Maggi C, de Braud F, Di Bartolomeo M. Combination or
single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and
meta-analysis of published trials. Crit Rev Oncol Hematol. 2015 Oct 9. pii: S10408428(15)30043-3. doi: 10.1016/j.critrevonc.2015.09.002.
23. Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M,
Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, Lo
Russo G. Systemic approach to malignant pleural mesothelioma: what news of
chemotherapy, targeted agents and immunotherapy? Tumori. 2015 Oct 15;0(0):0. doi:
10.5301/tj.5000436.
24. Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R,
Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F,
Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M,
Loupakis F, de Braud F. Single-Agent Panitumumab in Frail Elderly Patients With
Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light
Up New Hope. Oncologist. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.20150171
25. Pelosi G, Fabbri A, Tamborini E, Perrone F, Testi AM, Settanni G, Busico A, Centonze G,
Braidotti P, Bulfamante G, De Braud F, Garassino M, Pastorino U. Challenging Lung
Carcinoma with Coexistent ΔNp63/p40 and Thyroid Transcription Factor-1 Labeling
Within the Same Individual Tumor Cells. J Thorac Oncol. 2015 Oct;10(10):1500-2. doi:
10.1097/JTO.0000000000000553.
26. de Braud F, Cascinu S, Spitaleri G, Pilz K, Clementi L, Liu D, Sikken P, De Pas T. A
phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid
tumors. Ann Oncol. 2015 Nov;26(11):2341-6. doi: 10.1093/annonc/mdv354.
27. Zappasodi R, de Braud F, Di Nicola M. Lymphoma Immunotherapy: Current Status.
Front Immunol. 2015 Sep 1;6:448. doi: 10.3389/fimmu.2015.00448. eCollection 2015.
Review. PMID: 26388871
28. Pinciroli P, Won H, Iyer G, Canevari S, Colecchia M, Giannatempo P, Raggi D, Pierotti
MA, De Braud FG, Solit DB, Rosenberg JE, Berger MF, Necchi A. Molecular Signature of
Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clin Genitourin Cancer.
2015 Aug 7. pii: S1558-7673(15)00190-1. doi: 10.1016/j.clgc.2015.07.017
29. Bregni G, Galli G, Gevorgyan A, de Braud F, Di Cosimo S. Trastuzumab cardiac toxicity:
a problem we put our heart into. Tumori. 2015 Aug 3;0(0):0. doi: 10.5301/tj.5000393.
30. Pietrantonio F, Aprile G, Rimassa L, Franco P, Lonardi S, Cremolini C, Biondani P,
Sbicego EL, Pasqualetti F, Tomasello G, Niger M, Casagrande M, Ghidini M, Muni R,
Montrone S, Bergamo F, Berenato R, Fontanella C, Bozzarelli S, Moretto R, Battaglin F, Di
Bartolomeo M, de Braud F, Miceli R. A new nomogram for estimating survival in patients
with brain metastases secondary to colorectal cancer. Radiother Oncol. 2015 Sep 4. pii:
S0167-8140(15)00448-X. doi: 10.1016/j.radonc.2015.08.023
31. Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch
S, Rittweger K, Haller DG. Capecitabine Plus Oxaliplatin Compared With
Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results
of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol. 2015 Nov
10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107.
32. Pelosi G, Fabbri A, Papotti M, Rossi G, Cavazza A, Righi L, Tamborini E, Perrone F,
Settanni G, Busico A, Testi MA, Maisonneuve P, De Braud F, Garassino M, Valeri B,
Sonzogni A, Pastorino U. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next
Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic
Correlations to Emerge. J Thorac Oncol. 2015 Nov;10(11):1560-9. doi:
10.1097/JTO.0000000000000658.
33. Celio L, Bonizzoni E, De Braud F, Agustoni F, Aapro M. Should clinicians always
administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and
vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two
randomized studies. Support Care Cancer. 2015 Aug 6.
34. Pusceddu S, De Braud F, Festinese F, Bregant C, Lorenzoni A, Maccauro M, Milione M,
Concas L, Formisano B, Leuzzi L, Mazzaferro V, Buzzoni R. Evolution in the treatment of
gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a
systematic review. Future Oncol. 2015;11(13):1947-59. doi: 10.2217/fon.15.86.
35. Zanardi E, Verzoni E, Grassi P, Necchi A, Giannatempo P, Raggi D, De Braud F,
Procopio G. Clinical experience with temsirolimus in the treatment of advanced renal cell
carcinoma. Ther Adv Urol. 2015 Jun;7(3):152-61. doi: 10.1177/1756287215574457. Review.
PMID:26161146
36. Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone
F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M,
Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F. BRAF
codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal
cancer at favorable prognosis. Ann Oncol. 2015 Oct;26(10):2092-7. doi:
10.1093/annonc/mdv290.
37. Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomatà C, Fiano V, Cassingena A,
Siravegna G, Milione M, Cassoni P, De Braud F, Rudà R, Soffietti R, Venesio T, Bardelli
A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di
Nicolantonio F. Digital PCR quantification of MGMT methylation refines prediction of
clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann
Oncol. 2015 Sep;26(9):1994-9. doi: 10.1093/annonc/mdv272
38. Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, Antoniotti
C, de Braud F, Falcone A, Iacovelli R. First-line anti-EGFR monoclonal antibodies in
panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Crit
Rev Oncol Hematol. 2015 Oct;96(1):156-66. doi: 10.1016/j.critrevonc.2015.05.016.
39. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C,
Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M,
Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr
P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG,
Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus
dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind,
phase 3 randomised controlled trial. Lancet. 2015 Aug 1;386(9992):444-51. doi:
10.1016/S0140-6736(15)60898-4.
40. Pietrantonio F, Mazzaferro V, Miceli R, Cotsoglou C, Melotti F, Fanetti G, Perrone F,
Biondani P, Muscarà C, Di Bartolomeo M, Coppa J, Maggi C, Milione M, Tamborini E, de
Braud F. Pathological response after neoadjuvant bevacizumab- or cetuximab-based
chemotherapy in resected colorectal cancer liver metastases. Med Oncol. 2015 Jul;32(7):182.
doi: 10.1007/s12032-015-0638-3.
41. Raggi D, Mariani L, Giannatempo P, Lo Vullo S, Giardiello D, Nicolai N, Piva L, Biasoni
D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Calareso G, Magni M, Di Nicola M,
Verzoni E, Grassi P, Procopio G, De Braud F, Pizzocaro G, Salvioni R, Necchi A.
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors:
Implications for clinical practice, trial design, and molecular interrogation. Urol Oncol. 2015
Jul;33(7):332.e19-24. doi: 10.1016/j.urolonc.2015.04.008.
42. Pietrantonio F, Orlandi A, Inno A, Da Prat V, Spada D, Iaculli A, Di Bartolomeo M,
Morosi C, de Braud F. Bevacizumab-based neoadjuvant chemotherapy for colorectal
cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. Crit Rev Oncol
Hematol. 2015 Sep;95(3):272-81. doi: 10.1016/j.critrevonc.2015.04.008. Epub 2015 Apr 25.
Review.
43. Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P,
Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S,
Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A,
Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A,
Falconi M, Delle Fave G. Real-world study of everolimus in advanced progressive
neuroendocrine
tumors.
Oncologist.
2015
May;20(5):570.
doi:
10.1634/theoncologist.2014-0037erratum.
44. Falvella FS, Caporale M, Cheli S, Martinetti A, Berenato R, Maggi C, Niger M, Ricchini F,
Bossi I, Di Bartolomeo M, Sottotetti E, Bernardi FF, de Braud F, Clementi E,
Pietrantonio F. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine
dehydrogenase. Int J Mol Sci. 2015 Apr 21;16(4):8884-95. doi: 10.3390/ijms16048884.
Review.
45. Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG,
Bajetta E, Pelosi G, de Braud F, Floriani I, Miceli R. Osteopontin, E-cadherin, and βcatenin expression as prognostic biomarkers in patients with radically resected gastric
cancer. Gastric Cancer. 2015 Apr 11. PMID: 25862567
46. Grassi P, Verzoni E, Porcu L, Iacovelli R, de Braud F, Procopio G. Sites of disease as
predictors of outcome in metastatic renal cell carcinoma patients treated with first-line
sunitinib or sorafenib. Ther Adv Urol. 2015 Apr;7(2):59-68. doi10.1177/1756287215571809.
47. Petrelli F, Pietrantonio F, Cremolini C, Di Bartolomeo M, Coinu A, Lonati V, de Braud F,
Barni S. Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal
cancer: A systematic review and pooled-analysis. Eur J Cancer. 2015 Mar 17. pii: S09598049(15)00211-7. doi: 10.1016/j.ejca.2015.02.011.
48. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F,
Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance
A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani
JG, Aktan G, Long GV. Health-related quality of life impact in a randomised phase III
study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in
patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015 Mar 17. pii: S09598049(15)00220-8. doi: 10.1016/j.ejca.2015.03.004.
49. Falvella FS, Cheli S, Martinetti A, Mazzali C, Iacovelli R, Maggi C, Gariboldi M, Pierotti
MA, Di Bartolomeo M, Sottotetti E, Mennitto R, Bossi I, de Braud F, Clementi E,
Pietrantonio F. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet
chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol. 2015
Mar 17. doi: 10.1111/bcp.12631.
50. Lucibello M, Adanti S, Antelmi E, Dezi D, Ciafrè S, Carcangiu ML, Zonfrillo M, Nicotera
G, Sica L, De Braud F, Pierimarchi P. Phospho-TCTP as a therapeutic target of
Dihydroartemisinin for aggressive breast cancer cells. Oncotarget. 2015 Mar 10;6(7):52755291.
51. Di Cosimo S, Bianchi GV, Bregni G, de Braud F. Prognosis of women with early breast
cancer and PIK3CA mutations.Breast. 2015 Mar 12. pii: S0960-9776(15)00043-0. doi:
10.1016/j.breast.2015.02.028. [
52. Baratti D, Kusamura S, Maggi C, de Braud F, Deraco M, Di Bartolomeo M, Pietrantonio
F. In reply. Oncologist. 2015 Mar;20(3):e5. doi: 10.1634/theoncologist.2014-423.
53. Dugo M, Nicolini G, Tragni G, Bersani I, Tomassetti A, Colonna V, Del Vecchio M, De
Braud F, Canevari S, Anichini A, Sensi M. A melanoma subtype with intrinsic resistance to
BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
Oncotarget. 2015 Mar 10;6(7):5118-5133
54. Musella V, Pietrantonio F, Di Buduo E, Iacovelli R, Martinetti A, Sottotetti E, Bossi I,
Maggi C, Di Bartolomeo M, de Braud F, Daidone MG, Cappelletti V. Circulating tumor
cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF
wild-type colorectal cancer receiving cetuximab or panitumumab. Int J Cancer. 2015 Feb
20. doi: 10.1002/ijc.29493.
55.
Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M,
Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S. Predictive role of BRAF
mutations in patients with advanced colorectal cancer receiving cetuximab and
panitumumab: A meta-analysis. Eur J Cancer. 2015 Mar;51(5):587-594. doi:
10.1016/j.ejca.2015.01.054.
56. Crippa F, Agresti R, Sandri M, Mariani G, Padovano B, Alessi A, Bianchi G, Bombardieri
E, Maugeri I, Rampa M, Carcangiu ML, Trecate G, Pascali C, Bogni A, Martelli G, de
Braud F. 18F-FLT PET/CT as an imaging tool for early prediction of pathological
response in patients with locally advanced breast cancer treated with neoadjuvant
chemotherapy: a pilot study. Eur J Nucl Med Mol Imaging. 2015 Feb 12. 10.1007/s00259015-2995-8
57. Serpico D, Porcu L, Tessari A, Gevorgyan A, Bregni G, Galli G, de Braud F, Torri V, Di
Cosimo S. Disease progression pattern in metastatic breast cancer patients treated with antiHER2 therapies.Clin Transl Oncol. 2015 Jan 21. DOI 10.1007/s12094-015-1274-2
58. Di Bartolomeo M, Maggi C, Ricchini F, Pietrantonio F, Iacovelli R, de Braud F, Inno A.
Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. Clin Interv
Aging. 2015 Jan 5;10:127-33. doi: 10.2147/CIA.S54675. eCollection 2015. PMID:25584021
59. Zappasodi R, Ruggiero G, Guarnotta C, Tortoreto M, Tringali C, Cavanè A, Cabras AD,
Castagnoli L, Venerando B, Zaffaroni N, Gianni AM, De Braud F, Tripodo C, Pupa SM,
Di Nicola M. HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth
of human aggressive B-cell non-Hodgkin lymphoma. Blood 2015 Mar 12;125(11):1768-71.
doi: 10.1182/blood-2014-07-590034. Epub 2015 Jan 8.
60. Catania C, Maur M, Berardi R, Rocca A, Di Giacomo AM, Spitaleri G, Masini C, Pierantoni
C, González-Iglesias R, Zigon G, Tasciotti A, Giovannoni L, Lovato V, Elia G, Menssen
HD, Neri D, Cascinu S, Conte PF, de Braud F. The tumour-targeting immunocytokine
F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid
tumours and expansion into patients with metastatic breast cancer. Cell Adh Migr. 2015 Jan
2;9(1-2):14-21. doi: 10.4161/19336918.2014.983785.
61. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F,
Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014
Investigators. Collaborators First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.
62. Iacovelli R, Pietrantonio F, Palazzo A, Maggi C, Ricchini F, de Braud F, Di Bartolomeo M.
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine
or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol. 2014
Dec;78(6):1228-37. doi: 10.1111/bcp.12449
63. Inno A, Fanetti G, Di Bartolomeo M, Gori S, Maggi C, Cirillo M, Iacovelli R, Nichetti F,
Martinetti A, de Braud F, Bossi I, Pietrantonio F. Role of MGMT as biomarker in
colorectal cancer.World J Clin Cases. 2014 Dec 16;2(12):835-9. doi:
10.12998/wjcc.v2.i12.835. Review
64. Pietrantonio F, Iacovelli R, Di Bartolomeo M, de Braud F. FOLFIRI with cetuximab or
bevacizumab: FIRE-3. Lancet Oncol. 2014 Dec;15(13):e581. doi: 10.1016/S14702045(14)70397-3.
65. Iacovelli R, Verzoni E, Grassi P, Farcomeni A, de Braud F, Procopio G. Rationale and
protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line
treatment after pazopanib in patients with advanced renal cell carcinoma. Tumori. 2014
Nov-Dec;100(6):282e-5e. doi: 10.1700/1778.19296.PMID: 25688511
66. Pusceddu S, de Braud F, Concas L, Bregant C, Leuzzi L, Formisano B, Buzzoni R.
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study
to evaluate the activity and safety of everolimus in combination with octreotide LAR and
metformin in patients with advanced pancreatic neuroendocrine tumors. Tumori. 2014
Nov-Dec;100(6):286e-9e. doi: 10.1700/1778.19298.PMID:25688512
67. Serpico D, Trama A, Haspinger ER, Agustoni F, Botta L, Berardi R, Palmieri G, Zucali P,
Gallucci R, Broggini M, Gatta G, Pastorino U, Pelosi G, de Braud F, Garassino MC; on
behalf of TYME (TYmic MalignanciEs) Collaborative Group. Available evidence and new
biological perspectives on medical treatment of advanced thymic epithelial tumors.Ann
Oncol. 2014 Nov 19. pii: mdu527. [Epub ahead of print] Review
68. Procopio G, Testa I, Verzoni E, Iacovelli R, Grassi P, Galli G, De Braud F, Saravia D,
Salvioni R. Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell
Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of
Patients. Oncology. 2014 Nov 4;88(3):133-138.
69. Iacovelli R, Pietrantonio F, Farcomeni A, Maggi C, Palazzo A, Ricchini F, de Braud F, Di
Bartolomeo M. Chemotherapy or targeted therapy as second-line treatment of advanced
gastric cancer. A systematic review and meta-analysis of published studies. PLoS One. 2014
Sep 30;9(9):e108940. doi: 10.1371/journal.pone.0108940. eCollection 2014
70. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C,
Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M,
Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr
P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG,
Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K. Combined BRAF and MEK
inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014 Nov
13;371(20):1877-88. doi: 10.1056/NEJMoa1406037.
71. Iacovelli R, Santoni M, de Braud F, Cascinu S, Procopio G. Highlights from the ASCO
Genitourinary Symposium 2014: focus on renal and prostate cancer. Expert Rev Anticancer
Ther. 2014 Aug 27:1-3
72. Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti
KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F. Circulating biomarkers in
advanced colorectal cancer patients randomly assigned to three bevacizumab-based
regimens. Cancers (Basel). 2014 Aug 29;6(3):1753-68. doi: 10.3390/cancers6031753
73. Giannatempo P, Greco T, Mariani L, Nicolai N, Tana S, Farè E, Raggi D, Piva L,
Catanzaro M, Biasoni D, Torelli T, Stagni S, Avuzzi B, Maffezzini M, Landoni G, De
Braud F, Gianni AM, Sonpavde G, Salvioni R, Necchi A. Radiotherapy or chemotherapy
for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient
outcomes† Ann Oncol. 2014 Sep 11. pii: mdu447. [Epub ahead of print] Review.
74. Verzoni E, Pusceddu S, Buzzoni R, Garanzini E, Damato A, Biondani P, Testa I, Grassi P,
Bajetta E, de Braud F, Procopio G. Safety profile and treatment response of everolimus in
different solid tumors: an observational study. Future Oncol. 2014;10(9):1611-7. doi:
10.2217/fon.14.31
75. Iacovelli R, Santoni M, Verzoni E, Grassi P, Testa I, de Braud F, Cascinu S, Procopio G.
Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell
Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. Clin Genitourin
Cancer. 2014 Aug 2. pii: S1558-7673(14)00153-0. doi: 10.1016/j.clgc.2014.07.006
76. Necchi A, Giannatempo P, Paolini B, Lo Vullo S, Marongiu M, Farè E, Raggi D, Nicolai N,
Piva L, Catanzaro M, Biasoni D, Torelli T, Stagni S, Maffezzini M, Gianni AM, De Braud
F, Mariani L, Sonpavde G, Colecchia M, Salvioni R. Immunohistochemistry to Enhance
Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial
Cancer Receiving First-Line Chemotherapy. Clin Genitourin Cancer. 2014 Aug 8. pii:
S1558-7673(14)00174-8. doi: 10.1016/j.clgc.2014.08.002
77. Pietrantonio F, Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, Iacovelli
R, Miceli R, Bossi I, Leone G, Milione M, Pelosi G, de Braud F. Gain of ALK Gene
Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with
Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. PLoS One. 2014
Apr 1;9(4):e92147. doi: 10.1371/journal.pone.0092147. eCollection 2014.
78. Catania C, Radice D, Spitaleri G, Adamoli L, Noberasco C, Delmonte A, Vecchio F, de
Braud F, Toffalorio F, Goldhirsch A, De Pas T. The choice of whether to participate in a
phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study.
Psychooncology. 2014 Mar;23(3):322-9. doi: 10.1002/pon.3424. Epub 2013 Oct 10.PMID:
24123459
79. Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio
G.Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Pharmgenomics
Pers Med. 2014 Mar 27;7:107-116. eCollection 2014. Review. 249.
80. Procopio G, Verzoni E, Biondani P, Grassi P, Testa I, Garanzini E, De Braud F. Rationale
and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate
the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical
resection of the metastases. Tumori. 2014 Jan-Feb;100(1):28e-30e. doi:10.1700/1430.15834.
81. Necchi A, Giannatempo P, Mariani L, Farè E, Raggi D, Pennati M, Zaffaroni N, Crippa F,
Marchianò A, Nicolai N, Maffezzini M, Togliardi E, Daidone MG, Gianni AM, Salvioni R,
De Braud F. PF-03446962, a fully-human monoclonal antibody against transforming
growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an
open label, single-group, phase 2 trial. Invest New Drugs. 2014 Feb 26. Invest New
Drugs (2014) 32:555–560 DOI 10.1007/s10637-014-0074-9
82. Platania M, Valeri B, Marchianò A, Calareso G, Agustoni F, Haspinger E, Pusceddu S,
Garassino MC, Gelsomino F, de Braud F. Fatal case of hepatic portal venous gas
following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. Int
J Colorectal Dis. Int J Colorectal Dis. 2015 Mar;30(3):429-30. doi: 10.1007/s00384-0141993-9. Epub 2014 Aug 21
83. Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P,
Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu
S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A,
Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A,
Falconi M, Delle Fave G. Real-World Study of Everolimus in Advanced Progressive
Neuroendocrine Tumors. Oncologist. 2014 Aug 12. pii: theoncologist.2014-0037.
84. Procopio G, Verzoni E, De Braud F. Butterfly and Renal Cell Cancer: Out of Chaos
Comes Order. J Clin Oncol. 2014 Jul 28. pii: JCO.2014.56.4757.
85. Pietrantonio F, Maggi C, Fanetti G, Iacovelli R, Di Bartolomeo M, Ricchini F, Deraco M,
Perrone F, Baratti D, Kusamura S, Tamborini E, Castano A, Consonni PV, Bossi I,
Gavazzi C, Milione M, Pelosi G, de Braud F. FOLFOX-4 Chemotherapy for Patients
With Unresectable or Relapsed Peritoneal Pseudomyxoma. Oncologist. 2014
Aug;19(8):845-50. doi: 10.1634/theoncologist.2014-0106.
86. Pietrantonio F, Biondani P, Perrone F, Di Bartolomeo M, Pacifici M, Milione M, Melotti F,
Maggi C, Montemurro G, Bossi I, Mariani L, de Braud F. TP53 mutations in advanced
colorectal cancer: the dark side of the moon. Oncology. 2014;86(5-6):289-94. doi:
10.1159/000360088.
87. Pelosi G, Haspinger ER, Bimbatti M, Leone G, Paolini B, Fabbri A, Tamborini E, Perrone
F, Testi A, Garassino M, Maisonneuve P, de Braud F, Pilotti S, Pastorino U. Does
Immunohistochemistry Affect Response to Therapy and Survival of Inoperable Non-Small
Cell Lung Carcinoma Patients? A Survey of 145 Stage III-IV Consecutive Cases. Int J Surg
Pathol. 2014 Apr;22(2):136-48. doi: 10.1177/1066896913511527.
88. Celio L, de Braud F, Aapro M. Aprepitant versus dexamethasone for delayed emesis: what
is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron? J Clin
Oncol. 2014 Jul 10;32(20):2185-6. doi: 10.1200/JCO.2014.55.4352.
89. Simbolo M1, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, Melisi D, Malleo
G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C,
Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A.
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular
subgroups. Oncotarget. 2014 May 15;5(9):2839-52.
90. Buzzoni R, Pusceddu S, Bajetta E, De Braud F, Platania M, Iannacone C, Cantore M,
Mambrini A, Bertolini A, Alabiso O, Ciarlo A, Turco C1, Mazzaferro V. Activity and safety
of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior
chemotherapy: a phase II ITMO study. Ann Oncol. 2014 Aug;25(8):1597-603. doi:
10.1093/annonc/mdu175.
91. Iacovelli R, Verzoni E, De Braud FM, Procopio G. Study design and clinical evidence in
mRCC: can we save axitinib as a first-line therapy? Cancer Biol Ther. 2014 May;15(5):486-8.
doi: 10.4161/cbt.28161.
92. Biondani P, Verzoni E, Torri V, Porcu L, Grassi P, Testa I, DE Braud F, Procopio G.
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results
from a large cohort of patients. Anticancer Res. 2014 May;34(5):2395-8.
93. Toffalorio F, Spitaleri G, Catania C, Dal Zotto L, Noberasco C, Delmonte A, Santarpia M,
Vecchio F, Brunelli V, Rampinelli C, Barberis M, Fumagalli C, Zucchetti M, Zangarini M,
Diena T, Danesi R, de Braud F, De Pas T. Phase ib of sorafenib in combination with
everolimus in patients with advanced solid tumors, selected on the basis of molecular
targets.Oncologist. 2014 Apr;19(4):344-5. doi: 10.1634/theoncologist.2013-0335.
94. Seregni E, Maccauro M, Chiesa C, Mariani L, Pascali C, Mazzaferro V, De Braud F,
Buzzoni R, Milione M, Lorenzoni A, Bogni A, Coliva A, Vullo SL, Bombardieri E.
Treatment with tandem [90Y]DOTA-TATE and [ 177Lu]DOTA-TATE of neuroendocrine
tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging. 2014
Feb;41(2):223-30.
95. Procopio G, Testa I, Iacovelli R, Grassi P, Verzoni E, Garanzini E, Colecchia M, Torelli T,
DE Braud F. Treatment of collecting duct carcinoma: current status and future
perspectives. Anticancer Res. 2014 Feb;34(2):1027-30.
96. Haspinger ER, Garassino MC, Torri V, Cinquini M, De Braud F, Gelsomino F. Do We
Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in
First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR
Mutations? J Clin Oncol. 2014 Feb 3.
97. Lawler M, Le Chevalier T, Murphy MJ Jr, Banks I, Conte P, De Lorenzo F, Meunier F,
Pinedo HM, Selby P, Armand JP, Barbacid M, Barzach M, Bergh J, Bode G, Cameron DA,
de Braud F, de Gramont A, Diehl V, Diler S, Erdem S, Fitzpatrick JM, Geissler J,
Hollywood D, Højgaard L, Horgan D, Jassem J, Johnson PW, Kapitein P, Kelly J, Kloezen
S, La Vecchia C, Löwenberg B, Oliver K, Sullivan R, Tabernero J, Van de Velde CJ,
Wilking N, Wilson R, Zielinski C, Zur Hausen H, Johnston PG. A Catalyst for Change: The
European Cancer Patient's Bill of Rights. Oncologist. 2014 Feb 3.
98. Pietrantonio F, Perrone F, de Braud F, Castano A, Maggi C, Bossi I, Gevorgyan A,
Biondani P, Pacifici M, Busico A, Gariboldi M, Festinese F, Tamborini E, Di Bartolomeo
M. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer
and MGMT promoter methylation. Ann Oncol. 2014 Feb;25(2):404-8. doi:
10.1093/annonc/mdt547.
99. Di Cosimo S, Serpico D, Porcu L, Molino L, Fanetti G, Torri V, de Braud F. Clinical
Outcome of HER2-positive Breast Cancer Patients after Failure on Adjuvant Trastuzumab:
The Potential of the Time to Relapse. Clin Oncol (R Coll Radiol). 2014 Mar;26(3):174. doi:
10.1016/j.clon.2013.11.028.
100.
Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud
F, Tiseo M. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit
Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006.
101.
Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz
LH, Morosi C, Crippa F, Farè E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C,
Ortega C, De Braud FG, Salvioni R, Daidone MG, Gianni AM, Mariani L. Analysis of
plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer
receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic
accuracy. Br J Cancer. 2014 Jan 7;110(1):26-33. doi: 10.1038/bjc.2013.719.
102.
Agustoni F, Platania M, Vitali M, Zilembo N, Haspinger E, Sinno V, Gallucci R, de
Braud F, Garassino MC. Emerging toxicities in the treatment of non-small cell lung cancer:
Ocular
disorders.
Cancer
Treat
Rev.doi:pii:
S0305-7372(13)00097-2.
10.1016/j.ctrv.2013.05.005. Cancer Treat Rev. 2014 Feb;40(1):197-203. doi:
10.1016/j.ctrv.2013.05.005. Epub 2013 Jul 10.
103.
Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, Piva L, Biasoni
D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, De Braud FG, Gianni
AM, Salvioni R.Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC
Methotrexate /Vinblastine /Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable
or Metastatic Urothelial Cancer. Clin Genitourin Cancer. 2013 Nov 21. pii: S15587673(13)00293-0. doi: 10.1016/j.clgc.2013.11.022.
104.
Iacovelli R, Verzoni E, De Braud F, Procopio G. First line treatment of metastatic
renal cell carcinoma: Two standards with different toxicity profile. Cancer Biol Ther. 2014
Jan 1;15(1):19-21. doi: 10.4161/cbt.27150.
105.
Improta G, Pelosi G, Tamborini E, Donia M, Santinami M, de Braud F, Fraggetta
F.Biological insights into BRAFV600 mutations in melanoma patient: Not mere therapeutic
targets. Oncoimmunology. 2013 Aug 1;2(8):e25594. Epub 2013 Jul 3.PMID:24179707
106.
Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N,
Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I,
Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT,
Ruzzenente A, Guglielmi A, Tortora G, de Braud F, Scarpa A, Jarnagin W, Klimstra D,
Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N,
Wood LD.Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A
and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013 Dec;45(12):1470-3. doi:
10.1038/ng.2813.
107.
Verzoni E, de Braud F, Fabiani F, Grassi P, Testa I, Procopio G. Patient approach
in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatmentrelated toxicity. Future Oncol. 2013 Nov;9(11):1599-607. doi: 10.2217/fon.13.150.PMID:
24156321
108.
Catania C, Radice D, Spitaleri G, Adamoli L, Noberasco C, Delmonte A, Vecchio F,
de Braud F, Toffalorio F, Goldhirsch A, De Pas T. The choice of whether to participate in
a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory
study. Psychooncology. 2013 Oct 10. doi: 10.1002/pon.3424. [
109.
Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R, Valdagni R, de
Braud F. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients
With Concomitant Cardiovascular Risk Factors. Am J Clin Oncol. 2013 Sep 21.[Epub
ahead of print]PMID:24064757
110.
Pietrantonio F, Perrone F, Biondani P, Maggi C, Lampis A, Bertan C, Venturini F,
Tondulli L, Ferrari D, Ricci V, Villa F, Barone G, Bianco N, Ghidini A, Bossi I, Fanetti G,
Di Bartolomeo M, de Braud F. Single agent panitumumab in KRAS wild-type metastatic
colorectal cancer patients following cetuximab-based regimens: Clinical outcome and
biomarkers of efficacy. Cancer Biol Ther. 2013 Sep 4;14(12).
111.
Pérez-Vargas JC, Biondani P, Maggi C, Gariboldi M, Gloghini A, Inno A, Volpi CC,
Gualeni AV, di Bartolomeo M, de Braud F, Castano A, Bossi I, Pietrantonio F. Role of
cMET in the Development and Progression of Colorectal Cancer. Int J Mol Sci. 2013 Sep
3;14(9):18056-77. doi: 10.3390/ijms140918056.
112.
Grassi P, Verzoni E, Mariani L, De Braud F, Coppa J, Mazzaferro V, Procopio G.
Prognostic Role of Pancreatic Metastases From Renal Cell Carcinoma: Results From an
Italian Center. Clin Genitourin Cancer. 2013 Jun 19. doi:pii: S1558-7673(13)00083-9.
10.1016/j.clgc.2013.04.022.
113.
Damian S, Celio L, De Benedictis E, Mariani P, Agustoni F, Ricchini F, De Braud F.
Is a Dexamethasone-Sparing Strategy Capable of Preventing Acute and Delayed Emesis
Caused by Combined Doxorubicin and Paclitaxel for Breast Cancer? Analysis of a Phase II
Trial. Oncology. 2013 May 22;84(6):371-377.
114.
Pietrantonio F, Biondani P, Ciurlia E, Fanetti G, Tessari A, Bertarelli G, Bossi I,
Musella V, Melotti F, Di Bartolomeo M, Valvo F, Pellegrinelli A, Milione M, Perrone F, de
Braud F. Role of BAX for outcome prediction in gastrointestinal malignancies. Med
Oncol. 2013 Sep;30(3):610. doi: 10.1007/s12032-013-0610-z.
115.
Damato A, Pusceddu S, Milione M, Mazzaferro V, Magli M, Seregni E, De Braud
F, Buzzoni R. Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with
controversial medical opportunities. Tumori. 2013 Jul-Aug; 99(4):e148-51. doi:
10.1700/1361.15113.
116.
Celio L, Ricchini F, De Braud F. Safety, efficacy, and patient acceptability of singledose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and
vomiting. Patient Prefer Adherence. 2013 May 7;7:391-400. doi: 10.2147/PPA.S31288.
117.
Buzzoni R, Pusceddu S, Damato A, Meroni E, Cumali A, Milione M, Mazzaferro V,
De Braud F, Spreafico C, Maccauro M, Zaffaroni N, Castellani MR. Malignant
pheochromocytoma and paraganglioma: future considerations for therapy. Q J Nucl Med
Mol Imaging. 2013 Apr 18.
118.
Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M,
Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M. A review on biomarkers
for prediction of treatment outcome in gastric cancer. Anticancer Res. 2013
Apr;33(4):1257-66
119.
Pusceddu S, Buzzoni R, De Braud F. Pancreatic well-differentiated neuroendocrine
neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO
clinical practice guidelines in the therapeutic algorithm? Ann Oncol. 2013 May;24(5):1415-6.
doi: 10.1093/annonc/mdt102.
120.
Pelosi G, Rossi G, Cavazza A, Righi L, Maisonneuve P, Barbareschi M, Graziano P,
Pastorino U, Garassino M, de Braud F, Papotti M. ΔNp63 (p40) Distribution Inside Lung
Cancer: A Driver Biomarker Approach to Tumor Characterization. Int J Surg Pathol. 2013
Jun;21(3):229-39. doi: 10.1177/1066896913476750.
121.
Garassino MC, Platania M, Broggini M, Torri V, De Braud F. To Target or Not to
Target, That Is the Question. J Clin Oncol. 2013 Mar 20;31(9):1254. doi:
10.1200/JCO.2012.45.9818
122.
Bampo C, Alessi A, Fantini S, Bertarelli G, de Braud F, Bombardieri E, Valvo F,
Crippa F, Di Bartolomeo M, Mariani L, Milione M, Biondani P, Avuzzi B, Chiruzzi C,
Pietrantonio F. Is the Standardized Uptake Value of FDG-PET/CT Predictive of
Pathological Complete Response in Locally Advanced Rectal Cancer Treated with
Capecitabine-Based Neoadjuvant Chemoradiation?.Oncology. 2013 Jan 15;84(4):191-199.
123.
Pietrantonio F, Biondani P, Milione M, Melotti F, Bertarelli G, Perrone F, de Braud F,
Mariani L, Fanetti G, Cortinovis D, Di Bartolomeo M. Lack of Bax expression is associated
with irinotecan-based treatment activity in advanced colorectal cancer patients. Clin Transl
Oncol. 2012 Nov 21. [Epub ahead of print]
124.
Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, GonzálezIglesias R, Giovannoni L, Tasciotti A, Neri D, Menssen HD, de Braud F. Phase I/II study
of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in
patients with advanced solid tumours. J Cancer Res Clin Oncol. 2012 Nov 17.
125.
Procopio G, Verzoni E, de Braud F. Targeted Therapies and Survival: What We Can
Learn from Studies in Advanced Renal Cell Carcinoma. Oncology. 2013;84(1):39-42. Epub
2012 Oct 17.
126.
Díaz-Rubio E, Pietrantonio F, de Braud F. Continuing Single-Agent Bevacizumab as
Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in FirstLine Treatment of Metastatic Colorectal Cancer. Oncologist. 2012;17(11):1426-8. doi:
10.1634/theoncologist.2012-0075.
127.
Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte
A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci
M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in
patients with advanced solid tumours and multiple myeloma.Eur J Cancer. 2012 Oct 8.
doi:pii: S0959-8049(12)00723-X. 10.1016/j.ejca.2012.09.009
128.
Procopio G, Verzoni E, Iacovelli R, Biasoni D, Testa I, Porcu L, De Braud F.
Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with
targeted therapies. r J Cancer. 2012 Sep 11. doi: 10.1038/bjc.2012.327.
129.
Pietrantonio F, Garassino MC, Torri V, de Braud F. Reply to FOLFIRI plus
cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in
the randomised German AIO study KRK-0306. Ann Oncol. 2012 Aug 8
130.
Celio L, Agustoni F, Testa I, Dotti K, De Braud F. Palonosetron: an evidence-based
choice in prevention of nausea and vomiting induced by moderately emetogenic
chemotherapy. Tumori. 2012 May;98(3):279-86.
131.
Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C,
Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, De
Braud F, Gianni AM, Salvioni R. Pazopanib in advanced and platinum-resistant urothelial
cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012 Aug;13(8):810-6.
132.
Panzuto F, Campana D, Fazio N, Brizzi MP, Boninsegna L, Nori F, Di Meglio G,
Capurso G, Scarpa A, Dogliotti L, De Braud F, Tomassetti P, Delle Fave G, Falconi M.
Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors.
Neuroendocrinology 2012;96:32-40.
133.
Perrone F, de Braud F, Labianca R, Tomino C, Roila F. Tackling off-label use of
anticancer drugs. Clin Oncol. 2012 Aug 1;30(22):2800.
134.
Pietrantonio F, Biondani P, de Braud F, Pellegrinelli A, Bianchini G, Perrone F,
Formisano B, Di Bartolomeo M. Bax expression is predictive of favorable clinical outcome
in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and
irinotecan regimen. Transl Oncol. 2012 Jun;5(3):155-9.
135.
Pelosi G, Gasparini P, Cavazza A, Rossi G, Graziano P, Barbareschi M, Perrone F,
Barberis M, Takagi M, Kunimura T, Yamada T, Nakatani Y, Pastorino U, Scanagatta P,
Sozzi G, Garassino M, De Braud F, Papotti M. Multiparametric molecular characterization
of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic
lymphoma kinase (ALK) gene. Lung Cancer. 2012 Sep;77(3):507-14.
136.
Biondani P, Procopio G, Pietrantonio F, de Braud F, Verzoni E. New perspectives in
advanced genitourinary malignancies. Tumori. 2012 Mar-Apr; 98(2):267-9.
137.
Toffalorio F, Radice D, Spaggiari L, Sinno V, Barberis M, Spitaleri G, Giovannini M,
Delmonte A, Catania C, Noberasco C, Brambilla D, de Braud F, Veronesi G, Solli P, De
Pas T. Features and prognostic factors of large node-negative non-small-cell lung cancers
shifted to stage II. J Thorac Oncol. 2012 Jul;7(7):1124-30.
138.
M. Milione , S. Pusceddu, P. Gasparini, F. Melotti, P. Maisonneuve, V. Mazzaferro,
FG. de Braud and G.Pelosi Succinate Dehydrogenase B Subunit Immunohistochemical
Expression Predicts Aggressiveness in Wel Differentiated Neuroendocrine Tumors of
the Ileum. Cancers 2012, 4(3), 808-820;
doi:10.3390/cancers4030808
139.
Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F,
Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J; BIG 1-98
Collaborative Group; International Breast Cancer Study Group. Subjective cognitive
complaints one year after ceasing adjuvant endocrine treatment for early-stage breast
cancer. Br J Cancer. 2012 May 8;106(10):1618-25.
140.
Procopio G, Verzoni E, De Braud F. Re: Camillo Porta, Emiliano Calvo, Miguel A.
Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell
carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1
Trial. Eur Urol 2012; 61:826-33.
141.
De Pas T, Giovannini M, Rescigno M, Catania C, Toffalorio F, Spitaleri G, Delmonte A,
Barberis M, Spaggiari L, Solli P, Veronesi G, De Braud F. Vaccines in non-small cell lung
cancer: Rationale, combination strategies and update on clinical trials. Crit Rev Oncol Hematol.
2012 Sep;83(3):432-43.
142.
Spada F, Pelosi G, Squadroni M, Lorizzo K, Farris A, de Braud F., Fazio N.
Neuroendocrine tumour arising inside a retro-rectal tailgut cyst: report of two cases and a
review of the literature. Ecancermedicalscience. 2011;5:201.
143.
Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A,GonzálezIglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E,
Menssen HD, Neri D, Garbe C. A Dose-Escalation and Signal-Generating Study of the
Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients
with Metastatic Melanoma. Clin Cancer Res. 2011 Dec 15;17(24):7732-42. Epub 2011 Oct
25. PubMed PMID: 22028492.
144.
Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L,Forbes
JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann
B, de Braud F; BIG 1-98 Collaborative Group; International Breast Cancer Study Group
(IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for
postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 198 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011
Nov;12(12):1101-8. Epub 2011 Oct 20. PubMed PMID: 22018631; PubMed Central
PMCID: PMC3235950.
145.
Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan
MM, Goldhirsch A, Coates AS, de Braud F; BIG 1-98 Collaborative and International
Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98
trial is consistent in younger postmenopausal women and in those with chemotherapyinduced menopause.Breast Cancer Res Treat. 2012 Jan;131(1):295-306.Epub 2011 Sep 4.
PubMed PMID: 21892704.
146. De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C,Delmonte A,
Giovannini M, Spaggiari L, de Braud F, Barberis M. Activity of epidermal growth factor
receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare
epidermal growth factor receptor mutations.J Thorac Oncol. 2011 Nov;6(11):1895-901.
147. Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD, de Braud F;
InternationalBreast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting
Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial
comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal
women with hormone receptor-positive, early breast cancer. Breast Cancer Res. 2011 May
26;13(3):209.
148.
De Pas T, Rosati G, Spitaleri G, Boni C, Tucci A, Frustaci S, Scalamogna R, Radice D,
Boselli S, Toffalorio F, Catania C, Noberasco C, Delmonte A, Vecchio F, de Braud F.
Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a
new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
Chemotherapy. 2011;57(3):217-24.
149.
Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A,
De Braud F, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M. Metastatic and locally
advanced pancreatic endocrine carcinomas: analysis of factors associated with disease
progression. J Clin Oncol. 2011 Jun 10;29(17):2372-7.
150.
Joensuu H, De Braud F, Grignagni G, De Pas T, Spitalieri G, Coco P, Spreafico C,
Boselli S, Toffalorio F, Bono P, Jalava T, Kappeler C, Aglietta M, Laurent D, Casali PG.
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final
results of a phase II study. Br J Cancer. 2011 May 24;104(11):1686-90.
151.
Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M,
Gilberg F, Rittweger K, Schmoll HJ. Capecitabine plus oxaliplatin compared with
fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol.
2011 Apr 10;29(11):1465-71.
152.
De Pas TM, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G,
SpitaleriG, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, De Braud F.
Optimizing pemetrexed-gemcitabine combination in patients with advanced non-smallcell
lung cancer: a pharmacogenetic approach. J Thorac Oncol. 2011 Apr;6(4):768-73.
153.
Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A,Boselli S,
Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C,Colombi S,
Caligaris-Cappio F, Lambiase A, Bordignon C. Phase I study of NGR-hTNF, a selective
vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin
Cancer Res. 2011 Apr 1;17(7):1964-72.
154.
Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I,
Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus
FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann
Oncol. 2011 Jan 12.
155.
Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC,
McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk
O,Feltquate DM, Kollia G, Nuyten DS, Galbraith S. A phase I study to determine the
safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR
inhibitor,brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol.
2011Jun:22(6):1413-9.
156.
Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Maiello E, Bodei L,
Paganelli G, Delle Fave G, de Braud F. Biological targeted therapies in patients with
advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev. 2010 Nov;36
Suppl 3:S87-94. Review.
157.
Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C,
Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E,
Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud
F. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase
I clinical trial in patients with solid tumours and expansion into patients with advanced
renal cell carcinoma. Eur J Cancer.2010 Nov;46(16):2926-35.
158.
Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L,
Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F,
Lambiase A, Bordignon C. Activity and safety of NGR-hTNF, a selective vascular-targeting
agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer.
2010 Sep 7;
159.
De Pas T, de Braud F, Veronesi G. Adjuvant chemotherapy in new stage II pN0
non-small cell lung cancer: a new issue for a case-by-case decision making process. J Thorac
Oncol. 2010 May;5(5):754.
160.
Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N,
De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De
Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C. Phase II
study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular
targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin
Oncol. 2010 May 20;28(15).
161.
Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C,
Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM). Off-label
prescription of antineoplastic drugs: an Italian prospective, observational,
survey. Tumori. 2009 Nov-Dec;95(6):
multicenter
162.
Catania C, De Pas T, Minchella I, De Braud F, Micheli D, Adamoli L, Spitaleri G,
Noberasco C, Milani A, Zampino MG, Toffalorio F, Radice D, Goldhirsch A, Nolè F.
"Waiting and the Waiting Room: How Do You Experience Them?" Emotional
Implications and Suggestions from Patients with Cancer. J Cancer Educ. 2010 Mar 4.
163.
Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, Pessi MA, Prochilo
T, Quadri A, Gatta G, de Braud F, Wils J. Colon cancer. Crit Rev Oncol Hematol. 2010
May;74(2):106-33.
164.
De Pas T, Raimondi S, Pelosi G, Spaggiari L, De Braud F, Veronesi G, Maisonneuve
P. A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely
resected T3N0 non-small-cell lung cancer. Acta Oncol. 2010 May;49(4).
165.
Catania C, Pelosi G, Fazio N, Biffi R, Spitaleri G, Noberasco C, Zampino MG,
Maggioni A, Trifirò G, Toffalorio F, Vigna PD, De Braud F, De Pas T. A FOLFIRIinduced complete tumor response in a patient with FOLFOX-refractory metastatic
duodenal adenocarcinoma. Acta Oncol. 2010;49(1):120-1.
166.
Noberasco C, Spitaleri G, Mancuso P, Zorzino L, Radice D, Milani A, Rocca A,
Bertolini F, Sandri MT, Curigliano G, de Pas T, Jemos C, Omodeo Salè E, Boselli S, de
Braud F. Safety, tolerability and biological effects of long-term metronomic administration
of non-cytotoxic anti-angiogenic agents. Oncology. 2009;77(6):358-65
167.
Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, Minocci D,
Spaggiari L, Spitaleri G, Noberasco C, Catania C, Boselli S, Danesi R, de Braud F.
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.
Pharmacogenomics J. 2010 Jun;10(3):180-90.
168.
De Pas TM, Toffalorio F, Catania C, Noberasco C, Spitaleri G, Spaggiari L, De Braud
F. Gemcitabine and pemetrexed combination: the key role of the sequence of drugs
administration. Ann Oncol. 2009 Oct;20(10):1747-8. Epub 2009 Aug 18.
169.
Fazio N, Luca F, Monfardini L, Pelosi G, Bodei L, Lorizzo K, Di Meglio G, Gibelli B,
Ravizza D, Bonomo G, Grana CM, Baio S, Squadroni M, Paganelli G, de Braud F. Right
pelvic mass in a patient with a radically resected carcinoid of he appendix. Gut. 2009
Sep;58(9)
170.
Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M,
D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L. Phase I
clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J
Cancer. 2009 Aug;45(12):2116-22
171.
Curigliano G, Spitaleri G, De Cobelli O, Scardino E, Sbanotto A, de Braud F.
Health-related quality of life in patients with hormone refractory prostate cancer receiving
gefitinib. Urol Int. 2009; 82(2):196-202
172.
Capurso G, Fazio N, Festa S, Panzuto F, de Braud F, Delle Fave G. Molecular target
therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical
perspectives. Crit Rev Oncol Hematol. 2009 Feb 25.
173.
Zampino MG, Magni E, Leonardi MC, Petazzi E, Santoro L, Luca F, Chiappa A,
Petralia G, Trovato C, Fazio N, Orecchia R, Nolè F, de Braud F. Capecitabine Initially
Concomitant to Radiotherapy Then Perioperatively Administered in Locally Advanced
Rectal Cancer. Int J Radiat Oncol Biol Phys. 2009 Feb 9.
174.
Catalano G, De Pas T, Spaggiari L, Gandini S, Jereczek-Fossa BA, de Braud F, Leo
F, Veronesi G, Orecchia R. Three-times daily radiotherapy after chemotherapy in stage III
non-small cell lung cancer. Single-institution prospective study. Anticancer Res. 2008 NovDec; 28(6B):4121-7.
175.
Biffi R, Orsi F, Pozzi S, Pace U, Bonomo G, Monfardini L, Della Vigna P, Rotmensz
N, Radice D, Zampino MG, Fazio N, de Braud F, Andreoni B, Goldhirsch A. Best choice
of central venous insertion site for the prevention of catheter-related complications in adult
patients who need cancer therapy: a randomized trial. Ann Oncol. 2009 Jan 29
176.
Spitaleri G, Matei DV, Curigliano G, Detti S, Verweij F, Zambito S, Scardino E,
Rocco B, Nolè F, Ariu L, De Pas T, de Braud F, De Cobelli O. Phase II trial of
estramustine phosphate and oral etoposide in patients with hormone-refractory prostate
cancer. Ann Oncol. 2009 Mar; 20(3):498-502. Epub 2009 Jan 12. PubMed PMID:
19139180; PubMed Central PMCID: PMC2648011.
177.
Sessa C, Perotti A, Noberasco C, De Braud F, Gallerani E, Cresta S, Zucchetti M,
Viganò L, Locatelli A, Jimeno J, Feilchenfeldt JW, D'Incalci M, Capri G, Ielmini N, Gianni
L. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced
soft tissue sarcoma and breast cancer. Eur J Cancer. 2009 May; 45(7):1153-61. Epub 2008
Dec 27. PubMed PMID: 19114300.
178.
De Pas T, Spitaleri G, Pelosi G, De Carlis L, Lorizzo K, Locatelli M, Curigliano G,
Toffalorio F, Catania C, de Braud F. Erlotinib combined with cyclosporine in a livertransplant recipient with epidermal growth factor receptor-mutated non-small cell lung
cancer. J Thorac Oncol. 2009 Jan; 4 (1):138-9..
179.
Zampino MG, Labianca R, Beretta GD, Magni E, Gatta G, Leonardi MC, Chiappa A,
Biffi R, de Braud F, Wils J. Rectal cancer. Crit Rev Oncol Hematol. 2009 May; 70(2):16082. Epub 2008 Dec 6.
180.
Lorizzo K, Fazio N, Radice D, Boselli S, Ariu L, Zampino MG, Nolè F, Magni E,
Ardito R, Minchella I, Rocca A, Di Meglio G, Squadroni M, de Braud F. Simplified
FOLFIRI in pre-treated patients with metastatic gastric cancer. Cancer Chemother
Pharmacol. 2008 Nov 26. [
181.
Catania C, De Pas T, Goldhirsch A, Radice D, Adamoli L, Medici M, Verri E,
Marenghi C, de Braud F, Nolè F. Participation in clinical trials as viewed by the patient:
understanding cultural and emotional aspects which influence choice. Oncology. 2008; 74
(3-4):177-87.
182.
De Pas T, Toffalorio F, Colombo P, Trifirò G, Pelosi G, Vigna PD, Manzotti M,
Agostini M, de Braud F. Brief report: activity of imatinib in a patient with platelet-derivedgrowth-factor receptor positive malignant solitary fibrous tumor of the pleura. J Thorac
Oncol. 2008 Aug; 3 (8):938-41.
183.
Floriani I, Rotmensz N, Albertazzi E, Torri V, De Rosa M, Tomino C, de Braud F.
Approaches to interim analysis of cancer randomised clinical trials with time to event
endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials. Trials.
2008 Jul 25; 9:46.
184.
Zampino MG, Magni E, Santoro L, Zorzino L, Dell'orto P, Sonzogni A, Fazio N,
Monfardini L, Chiappa A, Biffi R, de Braud F. Epidermal growth factor receptor serum
(sEGFR) level may predict response in patients with EGFR positive advanced colorectal
cancer treated with gefitinib? Cancer Chemother Pharmacol. 2008 Dec; 63 (1):139-48.
185.
Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas
T, Goldhirsch A, Shah R. Drug-induced QTc interval prolongation: a proposal towards an
efficient and safe anticancer drug development. Eur J Cancer. 2008 Mar; 44 (4):494-500.
186.
Joensuu H, De Braud F, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S,
Jalava T, Laurent D, Casali PG. Phase II, open-label study of PTK787/ZK222584 for the
treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann
Oncol. 2008 Jan; 19 (1):173-7.
187.
De Pas T, Spitaleri G, Pruneri G, Curigliano G, Noberasco C, Luini A, Andreoni B,
Testori A, de Braud F. Dendritic cell sarcoma: an analytic overview of the literature and
presentation of original five cases. Crit Rev Oncol Hematol. 2008 Jan; 65 (1):1-7.
188.
Fazio N, Di Meglio G, Lorizzo K, de Brand F. Miliary Hepatic Metastases from
Neuroendocrine Carcinoma. Dig Surg. 2008 Oct 1; 25 (5):330. [Epub ahead of print] No
abstract available.
189.
Zampino MG, Magni E, Massacesi C, Zaniboni A, Martignetti A, Zorzino L, Lorizzo
K, Santoro L, Boselli S, de Braud F. First clinical experience of orally active epidermal
growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line
treatment for metastatic colorectal cancer. Cancer. 2007 Aug 15; 110 (4):752-8.
190.
Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, De Braud F,
Delle Fave G, Dogliotti L, Uberti EC; On behalf of the Italian CromaNet Working Group.
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
Endocr Relat Cancer. 2007 Jun; 14 (2):473-82.
191.
De Pas T, Spitaleri G, Pruneri G, Curigliano G, Noberasco C, Luini A, Andreoni B,
Testori A, de Braud F. Dendritic cell sarcoma: An analytic overview of the literature and
presentation of original five cases. Crit Rev Oncol Hematol. 2007 Jul 18;
192.
Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Koberle D, Borner MM,
Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de
Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil;
docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for
advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical
Cancer Research. J Clin Oncol. 2007 Aug 1;25 (22):3217-23.
193.
Curigliano G, De Braud F, Teresa Sandri M, Renne G, Zorzino L, Scardino E, Rocco
B, Spitaleri G, De Pas T, Noberasco C, Nole F, Verweij F, Matei V, De Cobelli O.
Gefitinib combined with endocrine manipulation in patients with hormone-refractory
prostate cancer: quality of life and surrogate markers of activity. Anticancer Drugs. 2007
Sep;18 (8):949-54.
194.
Joensuu H, De Braud F, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S,
Jalava T, Laurent D, Casali P. Phase II, open-label study of PTK787/ZK222584 for the
treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann
Oncol. 2007 Aug 14;
195.
Fazio N, Biffi R, Curigliano G, Lorizzo K, Zampino MG, de Braud F, Chiappa A,
Roth A, Goldhirsch A. Re: Adjuvant treatment of high-risk, radically resected gastric
cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a
randomized controlled trial. J Natl Cancer Inst. 2007 Sep 5;99 (17):1345-6; author reply
1346-7.
196.
Milani A, De Pas T, Noberasco C, McDonnell C, Libutti L, Limardi I, Zencovich C,
Boselli S, Bianchi M, de Braud F. A 15-min premedication for 1-h paclitaxel infusion:
optimizing patients' care. Lung Cancer. 2007 Nov;58 (2):300-1.
197.
Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas
T, Goldhirsch A, Shah R. Drug-induced QTc interval prolongation: A proposal towards an
efficient and safe anticancer drug development. Eur J Cancer. 2007 Nov 15;
198.
Zampino MG, Magni E, Massacesi C, Zaniboni A, Martignetti A, Zorzino L, Lorizzo
K, Santoro L, Boselli S, de Braud F. First clinical experience of orally active epidermal
growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line
treatment for metastatic colorectal cancer. Cancer. 2007 Aug 15;110 (4):752-8.
199.
Veronesi G, Scanagatta P, Leo F, De Pas T, Pelosi G, Catalano G, Gandini S,
deBraud F, Spaggiari L. Adjuvant surgery after carboplatin and VP16 in resectable small
cell lung cancer. J Thorac Oncol. 2007 Feb; 2 (2):131-4.
200.
Curigliano G, Pelosi G, De Pas T, Renne G, De Cobelli O, Manzotti M, Spitaleri G, de
Braud F. Absence of epidermal growth factor receptor gene mutations in patients with
hormone refractory prostate cancer not responding to gefitinib. Prostate. 2007 Feb 8;
201.
Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim
R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F,
Hill M, Sirzen F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant
therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol.
2007 Jan 1;25 (1):102-9.
202.
De Pas TM, de Braud F, Catalano G, Putzu C, Veronesi G, Leo F, Solli PG, Brambilla
D, Paganelli G, Spaggiari L. Oligometastatic non-small cell lung cancer: a multidisciplinary
approach in the positron emission tomographic scan era. Ann Thorac Surg. 2007 Jan;83
(1):231-4.
203.
Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS,
Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L.
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks
in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer.
2006 Nov 15;107 (10):2474-81.
204.
De Pas T, Putzu C, Curigliano G, Noberasco C, Sabrina B, Catania C, Orlando L,
Milani A, Spaggiari L, de Braud F. A proper schedule of weekly paclitaxel and gemcitabine
combination is highly Active and very well tolerated in NSCLC patients. Lung Cancer.
2006 Dec;54 (3):359-64.
205.
Curigliano G, Spitaleri G, de Braud F, Goldhirsch A. Reply to Letter to the Editor:
'Toxic epidermal necrolysis in patients with malignancies', by G. Gravante, G. Esposito, M.
Marianetti, D. Delogu, G. Sconocchia & A. Montone (doi:10.1093/annonc/mdl089). Ann
Oncol. 2006 Oct;17 (10):1601-2.
206.
Mey V, Giovanetti E, de Braud F, Nannizzi S, Curigliano G, Verweij F, de Corbelli O,
Pece S, Tacca MD, Danesi R. In vitro synergistic cytotoxicity of gemcitabine and
pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer
patients. Br J Cancer. 2006 Jul 25
207.
Fazio N, Grana C, Pelosi G, Torrisi R, Di Meglio G, Tradati N, Lorizzo K, de Braud
F. Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal aggressive
neuroendocrine carcinoma. Acta Oncol. 2006;45 (5):627-9
208.
Zampino MG, Lorizzo K, Rocca A, Locatelli M, Zorzino L, Manzoni S, Mazzetta C,
Fazio N, Biffi R, de Braud F. Oxaliplatin combined with 5-fluorouracil and methotrexate
in advanced colorectal cancer. Anticancer Res. 2006 May-Jun; 26 (3B).2425-8
209.
Fazio N, de Braud F, Fave GD, Oberg K. Interferon-{alpha} and somatostatin
analog in patients with gastroenteropancreatic neuroendocrine carcinoma : single agent or
combination ? Ann Oncol.2006 Jun 23
210.
Humbert M, Doumerc N, de Braud F, Fofana M, Blanchet P. Self-retaining ureteric
removal of an encrusted ureteric stent after 10 years Prog Urol. 2006 Apr;16 (2):204-7.
211.
Curigliano G, Magni E, Renne G, de Corbelli O, Rescigno M, Torrisi R, Spitaleri G,
Pietri E, de Braud F, Goldhirsch A.
“Burned out” phenomenon of the testis in
retroperitoneal seminoma. Acta Oncol. 2006;45 (3):335-6
212.
Curigliano G, Formica V, De Pas T, Spitaleri G, Pietri E, Fazio N, de Braud F,
Goldhirsch A. Life-threatening toxic epidermal necrolysis durino voriconazole therapy for
invasive aspergillosis after chemotherapy. Ann Oncol. 2006 Jul; 17(7):1174-5.
213.
Bracarda S, de Corbelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud
F, Bartsch G. Cancer of the prostate. Crit Rev Oncol Hematol. 2005 Dec; 56 (3):379-96
214.
Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A, Munzone E,
Rocca A, Bonizzi G, Brichard V, Orlando L, Goldhirsch A. Breast cancer vaccines: a
clinical reality or fairy tale? Ann Oncol. 2006 May; 17(5):750-62.
215.
Leon A, Torta M, Dittadi R, degli Uberti E, Ambrosio MR, Delle Fave G, de Braud F,
Tomassetti P, Gion M, Dogliotti L. Comparison between two methods in the
determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of
a prospective multicenter observational study. Int J Biol Markers. 2005 Jul-Sep; 20(3):15668
216.
Curigliano G, Colleoni M, Mandala M, De Pas T, Spitaleri G, de Braud F, Goldhirsch
A. Prophylaxis for venous thromboembolism in cancer patients with a central vein
catheter: new tones for an old song. J Clin Oncol. 2005 Oct 1; 23(28):7243-4; author reply
7244.
217.
Curigliano G, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, Gandini S,
Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A, Goldhirsch A. Systemic
Effects of Surgery : Quantitative Analysis of Circulating Basic Fibroblast Growth Factor
(bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor
Beta (TGF-beta) in Patients with Breast Cancer Who Underwent Limited or Extended
Surgery. Breast Cancer Res Treat. 2005 Sep.; 93(1):35-40
218.
De Pas T, Putzu C, Pelosi G, Curigliano G, Noberasco C, Zampino G, Fazio N,
Formica V, Spaggiari L, de Braud F Target-treatment and patients’ selection: can we still
neglect the timing of tissue collection? J Clin Oncol. 2005 Sep 1; 23(25):6275-5;author
reply 6275-6.
219.
Twelves CJ, Butts CA, Cassidy J, Conroy T, de Braud F, Diaz-Rubio E, Tabernero JM,
Schoffski P, Figer A, Brunet R, Grossmann J, Sobrero AF, Van Cutsem EJ.
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with
metastatic colorectal cancer: post hoc analysis of a large phase II study. Cli Colorectal
Cancer. 2005 Jul; 5 (2):101-7.
220.
Catalano G, Jereczek-Fossa BA, De Pas T, Leon ME, Cattani F, Spaggiari L, Veronesi
G, de Braud F, Orecchia R.
Three-Times-Daily Radiotherapy with Induction
Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer Feasibility and Toxicity
Study. Strahlenther Onkol. 2005 Jun; 181(6):363-371.
221.
Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric
Cancer. Crit Rev Oncol Hematol. 2005 Jun;54 (3):209-41
222.
Veronesi G, Pelosi G, Sonzogni A, Leon ME, D’Aiuto M, Gasparri R, de Braud F, De
Pas T, Sandri M, Spaggiari L. Tumor CEA as predictor of better outcome in squamous
cell carcinoma of the lung. Lung Cancer. 2005 May; 48(2):233-40.
223.
Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO,
Bonardi C, Garbi A, Dissoni A, de Braud F, Jimeno J, D’Incalci M. Anti-inflammatory
properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage
differentiation and cytokine production. Cancer Res. 2005 Apr 1; 65(7):2964-71.
224.
Mallik S, de Braud F, Fofana M, Humbert M, Clervil M, Blanchet P. Wich anaesthesia
should be recommended for prostate biopsy? West Indian Med J. 2005 Mar; 54(2):135-8
225.
Sessa C, de Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F,
Gianni L, Marsoni S, Jimeno J, D’Incalci M, Dall’o E, Colombo N. Trabectedin for
women with ovarian carcinoma after treatment with platinum and taxanes fails. J Cli Oncol.
2005 Mar 20; 23 (9):1867-74.
226.
de Braud F, De Pas T, Spaggiari L, Veronesi G, Curigliano G, Noberasco C, Pelosi G,
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung
cancer. J Natl Cancer Inst. 2005 Mar 16; 97(6):461-2; author reply 462-3.
227.
De Pas T, Sbanotto A, Catania C, Banfi MG, Curigliano G, Nole F, Fazio N, Formica
V, Veronesi G, de Braud F. Oral administration of vinorelbine can overcome intractable
endovenous-vinorelbine-associated acute tumor pain. Support Care Cancer. 2005 Mar;
13(3):194-5.
228.
De Pas T, Colleoni M, Orlando L, Masci G, Rocca A, Catania C, Curigliano G,
Manzoni S, Goldhirsch A, de Braud F. Reply to the artiche “Metronomic therapy with
cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of
toxicity” by V.R. Rozados et al. (Ann Oncol 2004;15:1543-1550): and in humans? Ann
Oncol. 2005 Apr; 16(4):673.
229.
Noberasco C, De Pas T, Curigliano G, Manzoni S, Dodaro L, Pelosi G, Spaggiari L, de
Braud F. Immunohistochemical detection of HER1/HER2 can be considered a
predective marker of gefitinib activity in non-small-cell lung cancer? J Clin Oncol. 2005
Feb 1; 23(4):921-2; author reply 922.
230.
Spaggiari L, D’Aiuto M, Veronesi G, Pelosi G, de Pas T, Catalano G, de Braud F.
Extended pneumonectomy with partila resection of the left atrium, without
cardiopulmonary bypass, for lung cancer. Ann Thorac Surg. 2005 Jan; 79 (1):234-40.
231.
De Pas T, Pelosi G, de Braud F, Veronesi G, Curigliano G, Leon ME, Danesi R,
Noberasco C, D’Aiuto M, Catalano G, Viale G, Spaggiari L. Modulation of epidermal
growth factor receptor status by chemotherapy in patients with locally advanced non-smallcell lung cancer is rare. J Clin Oncol.2004 Dec 15;22 (24):4966-70.
232.
Fazio N, De Pas T, de Braud F, Spaggiari L, Mazzarol G, Biffi R, Andreoni B,
Zampino M, Curigliano G, Lorizzo K, Di Meglio G, Goldhirsch A. CDX-2 should be
included in the work-up of patients with lung metastases from unknown primary. Ann
Oncol. 2004 Dec;15 (12):1850.
233.
Chiappa A, Zbar AP, Biffi R, Bellomi M, Orecchia R, Marsiglia H, Bertani E, de
Braud F, Crotti C, Andreoni B. Primary and recurrent retroperitoneal sarcoma: factors
affecting survival and long-term outcome. Hepatogastroenterology. 2004 Sep-Oct;51
(59):1304-9.
234.
De Pas T, Curigliano G, Veronesi G, Catalano G, Catania C, Jereczek-Fossa B,
Orecchia R, Spaggiari L, de Braud F. Optimization of the schedale of gemcitabinecisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2stage IIIb non-small-cell lung cancer: a prospective phase-II study. Bull Cancer. 2004 Sep
1; 91 (9):E273-7. Print 2004 Sep.
235.
Gennari R, Curigliano G, Rotmensz N, Robertson C, Colleoni M, Zurrida S, Nole F,
de Braud F, Orlando L, Leonardi MC, Galimberti V, Intra M, Veronesi P, Renne G,
Cinieri S, Audisio RA, Luini A, Orecchia R, Viale G, Goldhirsch A. Breast carcinoma in
elderly women: features of disease presentation, choice of local and systemic treatments
compared with younger postmenopausal patients. Cancer. 2004 Sep 15; 101 (6):1302-10.
236.
Jodrell DI, Evans TR, Steward W, Cameron D, Prendiville J, Aschele C, Noberasco C,
Lind M, Carmichael J, Dobbs N, Camboni G, Gatti B, de Braud F. Phase II studies of
BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastrooesophageal adenocarcinoma. Eur J Cancer. 2004 Aug; 40 (12):1872-7
237.
Labianca R, Beretta G, Gatta G, de Braud F, Wils J. Colon cancer Crit Rev Oncol
Hematol. 2004 Aug; 51 (2):145-70.
238.
Jereczek-Fossa BA, Morra A, de Braud F, Alterio D, Mazzetta C, Rocca A, Catalano
G, Bianchi L, Pasetti M, Chiesa F, Bruschini R, Orecchia R. Hyperfractionated
Radiotherapy in Locally Advanced Nasopharyngeal CancerAn Analysis of 43 Consecutive
Patients. Strahlenther Onkol. 2004 Jul; 180 (7):425-33.
239.
Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, de Braud F, Figer A,
Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E. XELOX
(capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal
cancer. J Clin Oncol. 2004 Jun 1; 22 (11):2084-91.
240.
Curigliano G, Cipolla C, de Braud F. Drug-induced prolongation of the QT interval.
N Engl J Med. 2004 Jun 17; 350 (25):2618-21
241.
de Braud F, Cascinu S, Gatta G. Cancer of pancreas.Crit Rev Oncol Hematol. 2004
May; 50 (2):147-55
242.
Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann R, Borner
MM, Goldhirsch A, de Braud F. 5-Fluorouracil as protracted continuous intravenous
infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric
carcinoma: a phase I-II trial. Ann Oncol. 2004 May; 15 (5):759-64.
243.
Leo F, Solli P, Spaggiari L, Veronesi G, de Braud F, Leon ME, Pastorino U.
Respiratory function changes after chemotherapy: an additional risk for postoperative
respiratory complications? Ann Thorac Surg. 2004 Jan; 77 (1):260-5; discussion 265.
244.
Loni L, de Braud F, Zinzani PL, Danesi R. Pharmacogenetics and proteomics of
anticancer drugs in non-Hodgkin's lymphoma.Leuk Lymphoma. 2003;44 Suppl 3: S115-22.
245.
Fazio N, Orsi F, Grasso RF, Ferretti G, Medici M, Rocca A, Zampino G, Curigliano
G, De Pas T, Colleoni M, Bonomo G, Marrocco E, Lunghi L, de Braud F. Hepatic intraarterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic
colorectal carcinoma. Anticancer Res. 2003 Nov-Dec; 23 (6D):5023-30
246.
Stahel R, Rossi A, Petruzelka L, Kosimidis P, de Braud F, Bernardo MM, Souquet PJ,
Parra HS, Gridelli C, Lessons from the (“Iressa” Expanded Access Programme: gefitinib in
special non-small-cell lung cancer patient populations. Br J Cancer. 2003 Dec; 89 Suppl
2:S19-23
247.
De Pas T, Danesi R, Catania C, Curigliano G, de Braud F; Italia Sarcoma Group.
Imatinib administration in two patients with liver metastases from GIST and severe
jaundice Br J Cancer. 2003 Oct 20; 89 (8):1403-4
248.
Danesi R, de Braud F, Fogli S, De Pas T, Di Paolo A, Curigliano G, Del Tacca M.
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol
Rev 2003 Mar; 55(1): 57-103.
249.
De Pas T, Bodei L, Pelosi G, de Braud F, Villa G, Capanna R, Paganelli G. Peptide
receptor radiotherapy: a new option for the management of aggressive fibromatosis on
behalf of the Italian Sarcoma Group. British Journal of Cancer 2003 Mar 10; 88 (5):645-7
250. de
Braud F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N.
melanoma Crit Rev Oncol Hematol. 2003 Jul; 47 (1):35-63. Review
Malignant
251.
Veronesi G, Spaggiari L, De Pas T, Solli PG, de Braud F, Catalano GP, Curigliano G,
Leo F, Pastorino U. Preoperative chemotherapy is essential for conservative surgery of
Askin tumors. Journal of Thoracic and Cardiovascular Surgery 2003 Feb; 125 (2): 428-9
252.
Ravizza D, Fazio N, Fiori G, Crosta C, Orsi F, Grasso R, Medici M, Ferretti G, de
Braud F. Iatrogenic gastroduodenal ulcers during hepatic intra-arterial chemotherapy.
Hepatogastroenterology 2003 Jan-Feb; 50: 49-53
253.
De Pas T, Casali PG, Toma S, Romanini A, Massidda B, Comandone A, Labianca R,
Massacesi C, Tucci A, Antimi M, Biasco G, Agliettaq M, Apice G, de Braud F.
Gastrointestinal stromal tumors: should they be treated with the same sistemic
chemotherapy as other soft tissue sarcomas? Oncology 2003; 64 (2): 186-8
254.
Orecchia R, Jereczek-Fossa BA, Catalano G, Chiesa F, De Pas T, Masci G, Krengli M,
Vavassori A, De Paoli F, Robertson C, Marrocco E, de Braud F. Phase II trial of
vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by
hyperfractionated radiotherapy in locally advanced head and neck cancer. Oncology 2002;
63 (2): 115-23
255.
Curigliano G, Colleoni M, Renne G, Mazzarol G, Gennari R, Peruzzotti G, de Braud
F, Robertson C, Maiorano E, Veronesi P, Nolè F, Mandalà M, Ferretti G, Viale G,
Goldhirsch A. Recognizing features that are dissimilar in male and female breast cancer
expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Annals of
Oncology 2002 Jun; 13 (6): 895-902
256.
De Pas T, Pastorino U, Spaggiari L, Curigliano G, de Braud F, Robertson C
Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease.
Journal of Clinical Oncology 2002 May 15; 20 (10): 2603-4
257.
Veronesi G, Solli PG, Leo F, D’Aiuto M, Leon ME, de Braud F, Spaggiari L,
Pastorino U. Low morbidity of bronchoplastic procedures after chemotherapy for lung
cancer. Lung Cancer 2002 Apr; 36 (1): 91-7
258.
Curigliano G, Ferretti G, Mandala M, De Pas T, Calabro MG, Solli P, Noberasc C, de
Braud F. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung
cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis.
Anticancer Research 2001 Sep-Oct; 21 (5): 3461-9
259.
de Braud F, Maffezzini M, Vitale V, Bruzzi P, Gatta G, Hendry WF, Sternberg CN.
Bladder cancer. Critical Review of Oncology and Hematology 2002 Jan; 41 (1): 89-106
260.
De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F.
Gemcitabine-induced systemic capillary leak syndrome. Annals of Oncology 2001 Nov; 12
(11): 1651-2
261.
Fogli S, Danesi R, de Braud F, De Pas T, Curigliano G, Giovannetti G, Del Tacca M.
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and
gemcitabine in patients with non-small-cell lung cancer. Annals of Oncology 2001 Nov; 12
(11): 1553-9
262.
Pfister CU, Martoni A, Zamagni C, Lelli G, de Braud F, Souppart C, Duval M,
Hornberger U. Effect of age and single versus multiple dose pharmacokinetics of letrozole
(Femara) in breast cancer patients. Biopharmaceutics and Drug Disposition 2001 Jul; 22 (5):
191-7
263.
Curigliano G, Ferretti G, Flamini G, Goldhirsch A, de Braud F, Calabro MG,
Mandala M, Nole F, De Pas T, D'Addessi A, Cittadini A.Diagnosis of T1 bladder
transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. Anticancer
Research 2001; 21: 3015-20
264.
Biffi R, Pozzi S, Pace U, Cenciarelli S, Zambelli M, Orsi F, Grasso RF, de Braud F,
Andreoni B. Is there a real advantage in utilizing central venous ports in oncology surgery?
An analysis of the cost-effectiveness ratio. Tumori 2001; 87: S74-5
265.
Biffi R, de Braud F, Orsi F, Pozzi S, Arnaldi P, Goldhirsch A, Rotmensz N,
Robertson C, Bellomi M, Andreoni B. A randomized, prospective trial of central venous
ports connected to standard open-ended or Groshong catheters in adult oncology patients.
Cancer 2001; 92: 1204-12
266.
Danesi R, de Braud F, Fogli S, Di Paolo A, Del Tacca M.
Pharmacogenetic
determinants of anti-cancer drug activity and toxicity. Trends in Pharmacological Sciences
2001; 22: 420-6
267.
Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi
F, De Cicco C, Macke HR, Chinol M, de Braud F. Receptor-mediated radiotherapy with
90Y-DOTA-D-Phe1-Tyr3-octreotide. European Journal of Nuclear Medicine 2001; 28:
426-34
268.
De Pas T, Catalano G, Pastorino U, de Braud F, Jereczek-Fossa B, Spaggiari L,
Orecchia R. Very low acute toxicity of three fractions per day accelerated radiotherapy
given after Induction chemotherapy and surgery in stage III non-small cell lung cancer.
Lung Cancer 2000; 30: 149-50
269.
Martinoni A, Cipolla CM, Civelli M, Cardinale D, Lamantia G, Colleoni M, DeBraud F,
Susini G, Martinelli G, Goldhirsh A, Fiorentini C. Intrapericardial treatment of neoplastic
pericardial effusions. Herz. 2000 Dec;25 (8):787-93. Review.
270.
De Pas T, de Braud F, Mandala M, Curigliano G, Catania C, Ferretti G, Sozzi P, Solli
P, Goldhirsch A.Cisplatin and vinorelbine as second-line chemotherapy in patients with
advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. Lung
Cancer 2001; 31: 267-70
271.
Biffi R, Orsi F, Grasso F, De Braud F, Cenciarelli S, Andreoni B. Catheter rupture
and distal embolisation: a rare complication of central venous ports. J Vasc Access. 2000
Jan-Mar;1 (1):19-22.
272.
Orsi F, Grasso RF, Arnaldi P, Bonifacio C, Biffi R, De Braud F, Bellomi M.
Ultrasound guided versus direct vein puncture in central venous port placement. J Vasc
Access. 2000 Apr-Jun; 1 (2):73-7.
273.
De Pas T, de Braud F, Danesi R, Sessa C, Catania C, Curigliano G, Fogli S, Del Tacca
M, Zampino G, Sbanotto A, Rocca A, Cinieri S, Marrocco E, Milani A, Goldhirsch A.
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemonaive
patients with advanced non-small-cell lung cancer. Annals of Oncology 2000; 11: 821-7
274.
Giavazzi R, Albini A, Bussolino F, de Braud F, Presta M, Ziche M, Costa A.
biological basis for antiangiogenic therapy Eur J Cancer. 2000 Oct; 36 (15): 1913-8
The
275.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes
Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de
Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without
oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical
Oncology 2000; 18: 2938-47
276.
Ferretti G, Curigliano G, Pastorino U, Cittadini A, Flamini G, Calabro MG, De Pas T,
Orlando L, Mandala M, Colleoni M, Spaggiari L, Granone PL, Pagliari G, de Braud F,
Fazio N, Goldhirsch A. Detection by denaturant gradient gel electrophoresis of tumorspecific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable
non-small cell lung cancer. Clinical Cancer Research 2000; 6: 2393-400
277.
De Pas T, Curigliano G, Catania C, Comandone A, de Braud F. Ifosfamide in the
elderly: clinical considerations for a better drug management. Critical Reviews in Oncology
and Hematology 2000; 33: 129-35
278.
Orlando L, Colleoni M, Nole F, Biffi R, Rocca A, Curigliano G, Ferretti G, Peruzzotti
G, de Braud F, Masci G, Goldhirsch A. Incidence of venous thromboembolism in breast
cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as
continuous infusion (ViFuP regimen): is prophylaxis required? Annals of Oncology 2000;
11: 117-8
279.
Biffi R, Pozzi S, Orsi F, de Braud F, Cenciarelli S, Andreoni B. Catheter rupture and
distal embolisation: a rare complication of central venous ports. Journal of Vascular
Access 2000; 1: 19-22
280.
De Pas T, Martinelli G, de Braud F, Peccatori F, Catania C, Aapro M, Goldhirsch A.
Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma.
Annals of Oncology 1999; 10: 1393
281.
Brienza S, Bensmaine MA, Soulie P, Louvet C, Gamelin E, Francois E, Ducreux M,
Marty M, Andre T, de Braud F, Bleiberg H, Segal V, Itzhaki M, Cvitkovic E. Oxaliplatin
added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated
patients with advanced colorectal carcinoma (ACRC): results from the European
compassionate-use program. Annals of Oncology 1999; 10: 1311-6
282.
Nole F, Minchella I, Colleoni M, Orvieto E, Munzone E, de Braud F, Peruzzotti G,
Martinelli G, Zampino MG, Catania C, Pizzamiglio M, Veronesi P, Zurrida S, Galimberti
V, Goldhirsch A, Veronesi U. Primary chemotherapy in operable breast cancer with
favorable prognostic factors: a pilotstudy evaluating the efficacy of a regimen with a low
subjective toxic burden containingvinorelbine, 5-fluorouracil and folinic acid (FLN). Annals
of Oncology 1999; 10: 993-6
283.
Casali P, Licitra L, Tondini C, de Braud F, Bruzzi P, Costa A, Cavalli F. START: a
European state-of-the-art on-line instrument for clinical oncologists. Annals of Oncology
1999; 10: 769-73
284.
Zampino MG, Colleoni M, Bajetta E, Stampino CG, Guenzi A and de Braud F.
Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. Tumori 1999; 85:
47-50
285.
Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, de Braud F, Robertson
C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U. Antibody-guided three-step
therapy for high grade glioma with yttrium-90 biotin. European Journal of Nuclear
Medicine 1999; 26: 348-57
286.
Crosta C, Fiori G, de Braud F. Endoscopic therapy of metastatic melanoma to the
papilla of water: a case report. Giornale Italiano di Endoscopia Digestiva 1999; 22: 157-9
287.
Colleoni M, Vicario G, Manente P, de Braud F, Fazio N, Liessi G. Activity and
tolerability of courses of intra-arterial chemotherapy followed by chemoembolization in
unresectable hepatocellular carcinoma. Tumori 1998; 84: 673-6
288.
De Pas T, de Braud F, Orlando L, Nole F, Munzone E, Zampino MG, Fazio N,
Aapro MS, Goldhirsch A. High-dose ifosfamide plus adriamycin in the treatment of adult
advanced soft tissue sarcomas: is it feasible? Annals of Oncology 1998; 9: 917-9
289.
Jereczek-Fossa B, de Braud F, Gasparetto M, De Pas T, Tradati N, Leonardi MC,
Marsiglia HR, Orecchia R. Induction chemotherapy followed by simultaneous
hyperfractionated radiochemotherapy in advanced head and neck cancer. A pilot study.
Strahlenther Onkologie 1998; 174: 457-61
290.
Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch A, Nole F, Andreoni B.
Totally implantable central venous access ports for long-term chemotherapy.
A
prospective study analyzing complications and costs of 333 devices with a minimum followup of 180 days. Annals of Oncology 1998; 9: 767-73
291.
Paganelli G, Orecchia R, Jereczek-Fossa B, Grana C, Cremonesi M, de Braud F,
Tradati N, Chinol M.
Combined treatment of advanced oropharyngeal cancer with
external radiotherapy and three-step radioimmunotherapy. European Journal of Nuclear
Medicine 1998; 25: 1336-9
292.
Audisio RA, de Braud F, Wils J.
Hematology 1998; 27: 143-4
Gastric cancer. Critical Reviews in Oncology and
293.
Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, Boni
C, Benavides M, Dallavalle G, Homerin M. Oxaliplatin as single agent in previously
untreated colorectal carcinoma patients: a phase II multicentric study. Annals of Oncology
1998; 9: 105-8
294.
Audisio RA, de Braud F, Wils J. Colorectal cancer. Critical Reviews in Oncology and
Hematology 1998; 27: 139-41
295.
De Pas T, de Braud F, Sessa C, Sbanotto A, Catania C, Zampino G, Minchella I,
Cinieri S, Colleoni M, Nolè F, Ghilenzan S, Marrocco E and Goldhirsch A Phase I doseescalation study with weekly taxol and gemcitabine in patients with advanced non small cell
lung cancer. Bulletin du Cancer 1998; 18 : 179-83
296.
Fazio N, de Braud F, Colleoni M, Orsi F, Marenghi C, Oliva C, De Pas T, Locatelli M
and Goldhirsch A Hepatic intra-arterial chemotherapy with fluorouracil, cisplatin and
mitomycin-c in liver metastases from colorectal carcinoma by percutaneous catheter.
Bulletin du Cancer 1998; 18: 120-3
297.
Colleoni M, Audisio RA, de Braud F, Fazio N, Martinelli G, Goldhirsch A. Practical
considerations in the treatment of hepatocellular carcinoma. Drugs 1998; 55: 367-82
298.
de Braud F, Munzone E, Nole F, De Pas T, Biffi R, Brienza S, Aapro MS.
Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal
cancer with progressive disease while on or after 5-fluorouracil. American Journal of
Clinical Oncology 1998; 21: 279-83
299.
Nole F, de Braud F, Aapro M, Minchella I, De Pas M, Zampino MG, Monti S,
Andreoni G, Goldhirsch A. Phase I-II study of vinorelbine in combination with 5fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a
regimen with a low subjective toxic burden. Annals of Oncology 1997; 8: 865-70
300.
Biffi R, Corrado F, de Braud F, de Lucia F, Scarpa D, Testori A, Orsi F, Bellomi M,
Mauri S, Aapro M, Andreoni B. Long-term, totally implantable central venous access ports
connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178
cases using a single type of device. European Journal of Cancer 1997; 33: 1190-4
301.
Colleoni M, Graffeo R, Martinelli G, Ghielmini M, de Braud F, Zampino G, Marini
G, Cavalli F and Goldhirsch A
Cisplatin, etoposide and bleomycin infusion (PEBi
regimen) in good-risk patients with germ cell tumors. Oncology Reports 1997; 4: 913-6
302.
de Braud F, Fazio N, Aapro M. Hormone replacement therapy and melanoma. CME
Journal of Gynecology and Oncology 1997; 15-7
303.
Peccatori F, de Braud F,Cocorocchio E, Aapro M Estrogen replacemnet therapy and
colorectal cancer: suggestion of protection. CME Journal of Gynecology and Oncology
1997; 21-2
304.
Janot F, Klijanienko J, Russo A, Mamet JP, de Braud F, El-Naggar AK, Pignon JP,
Luboinski B, Cvitkovic E. Prognostic value of clinicopathological parameters in head and
neck squamous cell carcinoma: a prospective analysis. British Journal of Cancer 1996; 73:
531-8
305.
de Braud F, De Pas T, Maffezzini M Immunoterapia del carcinoma renale avanzato.
Urologia 1996: 451-7
306.
Aapro MS, de Braud F, Tommasello G.
1996; 54, 35-8
Oncologie Médicale. Médicine et Hygiene
307.
Munzone E, de Braud F, de Pas M, Zimatore M, Aapro MS. Le traitment adjuvant
des tumeurs du colon et du rectum. Médicine et Hygiene 1996; 54, 1216-22
308.
Klijanienko J, el-Naggar AK, de Braud F, Rodriguez-Peralto JL, Rodriguez R, Itzhaki
M, Russo A, Janot F, Luboinski B, Cvitkovic E. Tumor vascularization, mitotic index,
histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous
cell carcinomas. Cancer 1995; 75: 1649-56
309.
Di Bartolomeo M, Bajetta E, de Braud F, Bochicchio AM, Gebbia V, Bozzetti F,
Doci R, Bonfanti G, Cozzaglio L. Phase II study of the etoposide, leucovorin and
fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive
chemotherapy. Oncology 1995; 52: 41-4
310.
de Braud F, Colleoni M, Noli F, Bajetta E. Home treatment with interleukin 2 and
beta-interferon in patients with colorectal cancer and hepatocellular carcinoma. Oncology
1994; 51: 472-6
311.
De Cesare M, Pratesi G, De Braud F, Zunino F, Stampino CG.
Remarkable
antitumor activity of 5'-deoxy-5-fluorouridine in human colorectal tumor xenografts.
Anticancer Research 1994; 14: 549-54
312.
Bajetta E, Di Bartolomeo M, de Braud F, Bozzetti F, Bochicchio AM, Comella P,
Fagnani D, Farina G, Ferroni C, Franchi R, et al. Etoposide, doxorubicin and cisplatin
(EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in
Medical Oncology (I.T.M.O.) Group. European Journal of Cancer 1994; 30A: 596-600
313.
de Braud F Le ròle de La thérapie medicale dans le traiment des tumeurs de l’etomac.
Médicine et Hygiene 1994; 52, 2386-9
314.
Klijanienko J, el-Naggar A, De Braud F, Micheau C, Janot F, Luboinski B, Gentile A,
Russo A, Cvitkovic E. Keratins 6, 13 and 19. Differential expression in squamous cell
carcinoma of the head and neck. Anal Quant Cytology and Histology 1993 Oct; 15 (5): 33540
315.
Gasparini M, Zampino MG, Maffioli L, de Braud F, Bombardieri E, Buraggi GL.
Enhancement of in vivo monoclonal antibody targeting with recombinant interferon a and
cytokines. International Journal of Biological Markers. 1993; 8: 160-5
316.
de Braud F, Bajetta E, Zampino MG, Zilembo N and Colleoni M.
Systemic
treatment of advanced malignant melanoma International Journal of Oncology 1993; 2:
245-52
317.
de Braud F, Biganzoli L, Bajetta E, Colleoni M, Zampino MG. Subcutaneous lowdose interleukin-2 plus alpha interferon in advanced malignant melanoma. Tumori 1993; 79:
187-90
318.
de Braud F, Al-Sarraf M. Diagnosis and management of squamous cell carcinoma of
unknown primary tumor site of the neck. Seminars in Oncology 1993; 20: 273-8
319.
Buzzoni R, Colleoni M, Bajetta E, Nole F, Nelli P, De Palma CA, de Braud F.
Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphoma. Annals
of Oncology 1993;4: 251-3
320.
Zilembo N, Buzzoni R, Bajetta E, Di Bartolomeo M, de Braud F, Castellani R,
Maffioli L, Celio L, Villa E, Lorusso V, et al. Salvage treatment after r-interferon alpha-2a in
advanced neuroendocrine tumors. Acta Oncologica 1993; 32: 245-50
321.
Di Bartolomeo M, Bajetta E, Zilembo N, de Braud F, Di Leo A, Verusio C, D'Aprile
M, Scanni A, Barduagni M, et al, Barduagni A. Treatment of carcinoid syndrome with
recombinant interferon alpha-2a. Acta Oncologica 1993; 32: 235-8
322.
Colleoni M, Bajetta E, de Braud F, Zilembo N, Nole F, Nelli P. Reversal of resistance
to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic
acid. Tumori 1992; 78: 258-61
323.
de Braud F, Bajetta E, Di Bartolomeo M, Colleoni M. Adjuvant chemotherapy for
cancer of gastrointestinal tract: a critical review. Tumori 1992; 78: 228-34
324.
Colleoni M, Nole F, Di Bartolomeo M, de Braud F, Bajetta E. Mitoxantrone in
patients affected by hepatocellular carcinoma with unfavorable prognostic factors.
Oncology 1992; 49: 139-42
325.
Capri G, de Braud F, Lissoni P, Merson M, Santoro O, Stefanon B, Tana S, Tancini G
Immunodepressione e tumori umani. NAM 1991; 7: 4-12
326.
Ensley JF, Maciorowski Z, Pietraszkiewicz H, de Braud F, Sakr W. Methodology and
clinical applications of cellular DNA content parameters determined by flow cytometry in
squamous cell cancers of the head and neck. Cancer Treatment and Research 1990; 52: 22542
327.
de Braud F, Heilbrun LK, Ahmed K, Sakr W, Ensley JF, Kish JA, Tapazoglou E, AlSarraf M Metastatic squamous cell carcinoma of an unknown primary localized to the neck.
Advantages of an aggressive treatment. Cancer 1989; 64: 510-5
328.
de Braud F Update on treatment of human neoplasia with interferons in combination
with other agents. Folia Oncologica 1989; 12-26
329.
de Braud F, Licitra L Diagnosi e trattamento dei carcinomi spinocellulare a sede
primitiva ignota metastatici ai linfonodi cervicali Argomenti di Oncologia 1989; 10: 447-57
330.
Orazi A, Sozzi G, Cattoretti G, de Braud F, Delia D. Acute leukemia with the (4;11)
chromosome translocation following treatment for Hodgkin's disease: a case study.
Haematologica 1988; 73: 279-83
331.
Campagnari F, Bombardieri E, de Braud F, Baldini L, Maiolo AT.
Terminal
deoxynucleotidyl transferase, TdT, as a marker for leukemia and lymphoma cells.
International Journal of Biological Markers 1987; 2: 31-42
332.
Delia D, Bonati A, Giardini R, Villa S, de Braud F, Cattoretti G, Rilke F. Expression
of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other
B-cell differentiation markers. Hematological Oncology 1986; 4: 237-48
333.
Delia D, Cattoretti G, Bonati A, Villa S, de Braud F, Buscaglia M. Detection of the
common acute lymphoblastic leukaemia antigen (CALLA) on B cells from human fetal
tissues. A multiple phenotypic characterization. Clinical and Experimental Immunology
1985; 59: 305-14
334.
Delia D, Greaves M, Villa S, de Braud F. Characterization of the response of human
thymocytes and blood lymphocytes to the synergistic mitogenicity of 12-Otetradecanoylphorbol-13-acetate (TPA)-ionomycin. European Journal of Immunology
1984; 14: 720-4
335.
Bombardieri E, Campagnari F, de Braud F, Clerici L, Maiolo AT, Villa ML,
Cappelletti V, Saccani Jotti G, Vezzoni P, Neri A, et al. Analysis of the enzyme terminal
deoxyribonucleotidyl transferase in lymphoma and leukemia cells. Acta Biomedica Ateneo
Parmense 1984; 55: 15-23
336.
Campagnari F, Maiolo AT, Bombardieri E, de Braud F. Terminal
deoxyribonucleotidyl transferase in malignant lymphoma and leukemia. Giornale di Clinica
Medica 1982; 412